Hi Triage, the cost of manufacturing a drug once it has been trialed and validated (i.e. through trials, failures etc) is low. The margins are high on the product. Hence why big pharma scoops up companies like $BOT who have done the hard work, with the big RnD spends.....
You're right. Sorry if I wasn't clear.
BOT - Anything but charting, page-211
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
0.015(3.30%) |
Mkt cap ! $858.0M | |||
| Open | High | Low | Value | Volume |
| 45.5¢ | 47.5¢ | 45.5¢ | $1.871M | 4.017M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 107654 | 46.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 133695 | 5 |
View Market Depth
| Last trade - 16.10pm 16/01/2025 (20 minute delay) ? |
| BOT (ASX) Chart |